Pre-registration is now open for the LGMD EL-PFDD Meeting with FDA and other stakeholders

The LGMD Coalition* is spearheading an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting on Friday, September 23, 2022. This initiative will focus on the four sarcoglycanopathies (LGMD2C/R5, 2D/R3, 2E/R4, and 2F/R6), LGMD2A/R1 (calpainopathy), and LGMD2I/R9 and will give the FDA and other key stakeholders an opportunity to hear directly from those living with LGMD and their families and caregivers.

This virtual meeting will include live speakers, pre-recorded panelists, and – throughout the day – live polling and discussion forums featuring YOU, our viewing audience. The morning session will focus on sub-type symptoms, their health effects, and the toll these six forms of LGMD take on your daily living. The afternoon session will highlight our community’s perspectives on currently available and future treatments and communicate our tolerance to risk. 

Visit us at lgmdpfdd.com for additional information about the EL-PFDD for LGMDs

*C3 is a member of “The LGMD Coalition,” a joint collaboration of six non-profit organizations involved in the planning of the September 23 EL-PFDD, which is the first of its kind for limb-girdle muscular dystrophy.